Merck & Co., Inc. (MRK) Stake Lessened by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 18.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 709,241 shares of the company’s stock after selling 160,135 shares during the period. Merck & Co., Inc. makes up approximately 1.9% of Edmond DE Rothschild Holding S.A.’s investment portfolio, making the stock its 14th largest position. Edmond DE Rothschild Holding S.A.’s holdings in Merck & Co., Inc. were worth $54,188,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Achmea Investment Management B.V. boosted its position in shares of Merck & Co., Inc. by 57.1% during the 4th quarter. Achmea Investment Management B.V. now owns 417,577 shares of the company’s stock worth $31,907,000 after purchasing an additional 151,799 shares during the period. PRW Wealth Management LLC purchased a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $41,000. Kiwi Wealth Investments Limited Partnership boosted its position in shares of Merck & Co., Inc. by 57.6% during the 4th quarter. Kiwi Wealth Investments Limited Partnership now owns 207,137 shares of the company’s stock worth $15,827,000 after purchasing an additional 75,669 shares during the period. ERTS Wealth Advisors LLC purchased a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $100,000. Finally, Stamos Capital Partners L.P. purchased a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $2,674,000. 72.57% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have commented on the stock. ValuEngine cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Zacks Investment Research raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $93.00 price target for the company in a research report on Monday, April 1st. UBS Group raised their price target on shares of Merck & Co., Inc. from $87.00 to $88.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. BMO Capital Markets reissued a “hold” rating on shares of Merck & Co., Inc. in a research report on Tuesday, February 19th. Finally, Atlantic Securities raised shares of Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a research report on Monday, May 13th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $82.92.

In other news, major shareholder Merck & Co., Inc. acquired 4,121,683 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was acquired at an average cost of $16.00 per share, with a total value of $65,946,928.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Frank Clyburn sold 25,000 shares of Merck & Co., Inc. stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $77.73, for a total transaction of $1,943,250.00. Following the sale, the executive vice president now directly owns 92,604 shares of the company’s stock, valued at $7,198,108.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 484,138 shares of company stock valued at $39,605,380. Corporate insiders own 0.27% of the company’s stock.

Merck & Co., Inc. stock opened at $81.02 on Friday. The firm has a market cap of $218.34 billion, a PE ratio of 18.67, a PEG ratio of 1.88 and a beta of 0.58. Merck & Co., Inc. has a 12-month low of $58.03 and a 12-month high of $83.85. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.37 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, April 30th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.17. The business had revenue of $10.82 billion during the quarter, compared to analysts’ expectations of $10.45 billion. Merck & Co., Inc. had a net margin of 19.50% and a return on equity of 39.85%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.05 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 4.72 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Merck & Co., Inc. (MRK) Stake Lessened by Edmond DE Rothschild Holding S.A.” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/24/merck-co-inc-mrk-stake-lessened-by-edmond-de-rothschild-holding-s-a.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Debt-To-Equity Ratio

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.